Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Editas Medicine Inc(EDIT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EDIT
10/28/2026: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.
Editas Medicine is a clinical-stage biotechnology company focused on developing CRISPR-based gene-editing therapies. Its main strength lies in a robust intellectual property foundation, though the company lacks a commercial product, making it highly dependent on clinical trial outcomes. The investment story centers on the potential of its lead candidate, reni-cel, to treat hemoglobinopathies, balanced against intense competition from better-capitalized peers. Key risks include significant financial burn, execution hurdles, and the regulatory uncertainty inherent in gene therapy. This stock suits risk-tolerant investors looking for long-term growth exposure to genomics; developments regarding clinical data and cash runway are critical factors to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the gene-editing space but currently lacks established growth metrics. |
| Momentum investor | Mixed fit | This style is conditional on a positive Upturn signal following major clinical trial milestones or positive data readouts. |
| Value investor | Weak fit | The stock lacks the profitability or tangible book value typical of value investment strategies. |
| Dividend investor | Weak fit | As a loss-making biotechnology firm, the company does not pay a dividend. |
| Low-risk investor | Weak fit | High volatility and the inherent uncertainty of clinical development make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings driven by clinical trial news and biotech market sentiment. |
| Valuation risk | Medium / high | Valuations in the biotech space are often speculative and highly sensitive to pipeline success expectations. |
| Competition risk (CRISPR/Gene Editing) | High | The presence of larger, better-funded competitors poses a significant threat to market entry and commercialization prospects. |
| Business quality | Medium | While the platform technology is sophisticated, the company lacks a self-sustaining commercial franchise. |
| Dividend income | Low / none | Investors should expect zero income generation from this equity. |
| Execution risk | High | The company faces immense challenges in successfully navigating the clinical trial and regulatory approval process. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 12.1% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 399.31M USD | Price to earnings Ratio - | 1Y Target Price 6.1 |
Price to earnings Ratio - | 1Y Target Price 6.1 | ||
Volume (30-day avg) 3.0M shares | Beta 2 | 52 Weeks Range 1.66 - 3.94 | Updated Date 10/28/2026 |
52 Weeks Range 1.66 - 3.94 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Licensing and Collaboration | Revenue from licensing proprietary CRISPR technology and milestone payments from research partnerships. | Revenue is irregular and depends on scientific partnership milestones rather than product sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 172.46M | Price to Sales(TTM) 8.49 |
Enterprise Value 172.46M | Price to Sales(TTM) 8.49 | ||
Enterprise Value to Revenue 3.7 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 153.58M | Shares Floating 115.49M |
Shares Outstanding 153.58M | Shares Floating 115.49M | ||
Percent Insiders 0.18 | Percent Institutions 79.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.